光动力疗法
医学
转移性乳腺癌
癌症研究
免疫疗法
光敏剂
乳腺癌
原发性肿瘤
免疫系统
化学
癌症
肿瘤科
转移
内科学
免疫学
有机化学
作者
Yanjuan Huang,Zilin Guan,Xiuling Dai,Yifeng Shen,Wei Qin,Lingling Ren,Jingwen Jiang,Zidong Xiao,Yali Jiang,Di Liu,Zeqian Huang,Xiaoyu Xu,Yong Luo,Chunshun Zhao
标识
DOI:10.1038/s41467-021-24564-0
摘要
Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this work, engineered macrophages (Oxa(IV)@ZnPc@M) carrying nanomedicine containing oxaliplatin prodrug and photosensitizer are designed as near-infrared (NIR) light-activated drug vectors, aiming to achieve enhanced chemo/photo/immunotherapy of primary and bone metastatic tumors. Oxa(IV)@ZnPc@M exhibits an anti-tumor M1 phenotype polarization and can efficiently home to primary and bone metastatic tumors. Additionally, therapeutics inside Oxa(IV)@ZnPc@M undergo NIR triggered release, which can kill primary tumors via combined chemo-photodynamic therapy and induce immunogenic cell death simultaneously. Oxa(IV)@ZnPc@M combined with anti-PD-L1 can eliminate primary and bone metastatic tumors, activate tumor-specific antitumor immune response, and improve overall survival with limited systemic toxicity. Therefore, this all-in-one macrophage provides a treatment platform for effective therapy of primary and bone metastatic tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI